Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1-month INH/RPT for LTBI in renal transplant candidates
NCT05411744Phase 4Active, not recruiting
- Sponsor
- Rutgers University
- Start
- Jul 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rifapentine and isoniazid in Tuberculosis (TB), sponsored by Rutgers University. Primary endpoint: Rate of adverse events at 28 days. Started Jul 2022; status: active, not recruiting.
02
Drugs
rifapentineisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05411744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411744.